US drugmaker AbbVie (NYSE: ABBV) was trading 3% higher early afternoon Thursday, after the Chicago-based firm earlier presented its financial results for the second quarter of 2024, and its latest projections for the rest of the year.
Worldwide net revenues were $14.46 billion, an increase of 4.3% on a reported basis and beating estimates of $14.03 billion. On an adjusted basis, AbbVie earned $2.65 per share, exceeding estimates by $0.08.
'Ahead of expectations'
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze